Novel algorithm for diagnosis of Arrhythmogenic cardiomyopathy and dilated cardiomyopathy: Key gene expression profiling using machine learning

Abstract

Background: It is difficult to distinguish between arrhythmogenic cardiomyopathy (ACM) and dilated cardiomyopathy (DCM) because of their similar clinical manifestations. This study aimed to develop a novel diagnostic algorithm for distinguishing ACM from DCM.Methods: Two public datasets containing human ACM and DCM myocardial samples were used. Consensus clustering, non-negative matrix factorization and principal component analysis were applied. Weighted gene co-expression network analysis and machine learning methods, including random forest and the least absolute shrinkage and selection operator, were used to identify candidate genes. Receiver operating characteristic curves and nomograms were performed to estimate diagnostic efficacy, and Spearman's correlation analysis was used to assess the correlation between candidate genes and cardiac function indices.Results: Both ACM and DCM showed highly similar gene expression patterns in the clustering analyses. Hub gene modules associated with cardiomyopathy were obtained using weighted gene co-expression network analysis. Thirteen candidate genes were selected using machine learning algorithms, and their combination showed a high diagnostic value (area under the ROC curve = 0.86) for distinguishing ACM from DCM. In addition, TATA-box binding protein associated factor 15 showed a negative correlation with cardiac index (R = À0.54, p = 0.0054) and left ventricular ejection fraction (R = À0.48, p = 0.0015).Conclusions: Our study revealed an effective diagnostic model with key gene signatures, which indicates a potential tool to differentiate between ACM and DCM in clinical practice. In addition, we identified several genes that are highly related to cardiac function, which may contribute to our understanding of ACM and DCM.Youming Zhang, Jiaxi Xie and Yizhang Wu contributed equally and share the first authorship.

Transcriptome and single‐cell sequencing analysis in tumor microenvironment

“…8 On the other hand, artificial intelligence (AI) and machine learning (ML) also have the potential to transform the field of bioinformatics and tumor analysis. 9 Artificial intelligence (AI) and machine learning (ML) are revolutionizing cancer research by providing powerful tools for analyzing complex data sets and generating new insights into the underlying biology of cancer. AI and ML have the potential to transform cancer diagnosis, treatment, and prevention by enabling personalized medicine approaches and improving patient outcomes.…”

“…One of the main applications of AI and ML in cancer research is in the analysis of large data sets, such as genomics, transcriptomics, and imaging data. 9 Machine learning algorithms can identify patterns and relationships in the data that would be difficult or impossible to detect by human analysis alone. For example, ML algorithms can be used to classify cancer subtypes based on genomic or transcriptomic data, predict patient outcomes, and identify new therapeutic targets.…”

“…10 In addition to data analysis, AI and ML are also being used to develop new diagnostic and treatment strategies. 9 For example, ML algorithms can be used to analyze medical images, such as computed tomography scans or magnetic resonance imaging, to identify tumors and monitor their growth over time. AI-based diagnostic tools can also help physicians make more accurate and timely diagnoses, leading to improved patient outcomes.…”

“…AI and ML have the potential to transform cancer diagnosis, treatment, and prevention by enabling personalized medicine approaches and improving patient outcomes. One of the main applications of AI and ML in cancer research is in the analysis of large data sets, such as genomics, transcriptomics, and imaging data 9 . Machine learning algorithms can identify patterns and relationships in the data that would be difficult or impossible to detect by human analysis alone.…”

“…For example, ML algorithms can be used to classify cancer subtypes based on genomic or transcriptomic data, predict patient outcomes, and identify new therapeutic targets 10 . In addition to data analysis, AI and ML are also being used to develop new diagnostic and treatment strategies 9 . For example, ML algorithms can be used to analyze medical images, such as computed tomography scans or magnetic resonance imaging, to identify tumors and monitor their growth over time.…”